Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide

87Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Several tumors overexpress somatostatin receptors (SSTR) and can thus be imaged with radiolabeled analogues of somatostatin. Tc-99m depreotide is a new radiolabeled somatostatin analogue that shows high affinity for SSTR2, SSTR3, and SSTR5 subtypes. It has been recently FDA-approved for use in the evaluation of indeterminate solitary pulmonary nodules. SPECT with Tc-99m depreotide is highly accurate in this clinical setting and may be preferable to FDG-PET because of its lower cost and wider availability. Large studies are also underway to evaluate the accuracy of Tc-99m depreotide in staging of lung cancer. Copyright 2002, Elsevier Science (USA). All rights reserved.

Cite

CITATION STYLE

APA

Menda, Y., & Kahn, D. (2002). Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Seminars in Nuclear Medicine, 32(2), 92–96. https://doi.org/10.1053/snuc.2002.31564

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free